Hawaii Biotech, Inc. (HBI) is a privately held biotechnology company founded in 1982 and focused on the research and development of vaccines for both established and emerging infectious diseases and small molecule medical countermeasure drugs designed to provide superior clinical efficacy.
We have sold one of our lead vaccine candidates to a large pharmaceutical partner after safety and immunogenicity data has been obtained from initial clinical studies. Out-licensing and partnering our protein production capabilities, vaccines, and adjuvant to interested parties continues to drive our business model. HBI has a strong track record of securing non-dilutive funding from grants and contracts from the National Institute of Health and the Department of Defense and has also raised private equity capital to support our research and development programs, allowing us to maintain a stream of revenues from multiple sources.
Hawaii Biotech, Inc. (HBI) is a privately held biotechnology company founded in 1982 and focused on the research and development of vaccines for both established and emerging infectious diseases and small molecule medical countermeasure drugs designed to provide superior clinical efficacy.
We have sold one of our lead vaccine candidates to a large pharmaceutical partner after safety and immunogenicity data has been obtained from initial clinical studies. Out-licensing and partnering our protein production capabilities, vaccines, and adjuvant to interested parties continues to drive our business model. HBI has a strong track record of securing non-dilutive funding from grants and contracts from the National Institute of Health and the Department of Defense and has also raised private equity capital to support our research and development programs, allowing us to maintain a stream of revenues from multiple sources.